Montelukast in Seasonal Allergic Rhinitis - Fall 1999 Study (0476A-117)

• Status: Completed
• Trial end date: 1999-11-01
• Target enrollment: 0
• Participant gender: All

Summary

This study will evaluate the ability of oral montelukast/loratadine to improve the signs and symptoms of seasonal allergic rhinitis compared with loratadine alone, montelukast alone and placebo.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Merck Sharp & Dohme Corp.
• Treatments: Loratadine; Montelukast

Criteria

Inclusion Criteria:

• Patient has a documented history of seasonal allergic rhinitis symptoms that flare up during the study season

• Patient is a nonsmoker

• Patient is in good general health

Exclusion Criteria:

• Patient is hospitalized

• Patient is a woman who is less than 8 weeks postpartum or is breast-feeding

• Patient intends to move or vacation away during the study

• Patient has had any major surgery within 4 weeks of study start

• Patient is a current or past abuser of alcohol or illicit drugs

• Patient has been treated in an emergency room for asthma in the past month

• Patient had an upper respiratory infection with in 3 weeks prior to study start

• Patient has any active pulmonary disorder other than asthma